[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples